News|Articles|May 28, 2025

Do New Antiobesity Meds Still Require Lifestyle Management?

Listen

0:00 / 0:00

Key Takeaways

Pharmacotherapy targets appetite signaling, yet lifestyle modification addresses environmental and behavioral drivers that medications cannot fully correct, particularly for cardiometabolic comorbidity control.
Intensive behavioral therapy provides structured goal setting, self‑monitoring, and problem solving that improves adherence to GLP‑1/GIP agents and sustains weight loss trajectories.
STEP and SURMOUNT trial programs demonstrate larger and more durable reductions when lifestyle counseling is embedded, and they highlight rapid regain after discontinuation without ongoing behavioral support.
Look AHEAD reinforces that intensive lifestyle intervention yields meaningful improvements in fitness, glycemia, and quality-of-life, informing integrated care models and reimbursement-ready nutrition counseling services.

Are lifestyle interventions still necessary when medications like semaglutide and tirzepatide are so effective?

Learn How To Introduce a Turnkey Evidence Based Nutrition Counseling Program to Your Practice.

Discover evidence-based guidance on how and why lifestyle counseling remains a cornerstone of obesity care—even in the era of highly effective, hormone-based pharmacotherapy.

Inside you'll learn:

Why lifestyle management remains foundational—even with GLP-1 and GIP-based medications
The clinical value of intensive behavioral therapy (IBT) alongside pharmacologic treatment
Key findings from STEP, SURMOUNT, and Look AHEAD trials

Adding a lifestyle management nutrition counseling program to your practice has both clinical and economic benefits.

Sponsored by:

Stay informed with the Medical Economics eNewsletter, delivering expert insights, financial strategies, practice management tips, and technology trends tailored for today’s physicians.